证券代码：688613 证券简称：奥精医疗 公告编号：2025-039 奥精医疗科技股份有限公司（以下简称"公司"或"本公司"）为规范公 司募集资金的存放、使用与管理，提高资金使用效率和效益，保护投资者权益，根 据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等法 律法规、规范性文件以及相关规定，本公司及子公司北京奥精医疗器械有限责任 公司、山东奥精生物科技有限公司、潍坊奥精健康科技有限公司、嘉兴奥精生 物科技有限公司在商业银行开设了募集资金专项账户，用于项目实施时的募集 资金存放。 1 截至本公告披露日，公司及上述子公司、华泰联合证券有限责任公司（以 下简称"华泰联合"或"保荐机构"）已与招商银行股份有限公司北京分行、兴 业银行股份有限公司北京中关村支行、华夏银行股份有限公司北京分行分别签订 《募集资金三方监管协议》、《募集资金四方监管协议》。 | 开户银行 | 银行账号 | 账户类别 | 账户状态 | | --- | --- | --- | --- | | 兴业银行股份有限公司北京中关 | 321070100100447453 | 募集资金专户 | 本次注销 | | 村支行 | | | ...

转自：前瞻产业研究院 口腔种植产业链上游原材料与核心部件供应商主要有爱尔创、康拓医疗、国瓷材料、正海生物、奥精医 疗等;设备制造商主要有美亚光电、爱迪特等;软件开发商主要有阳普医疗等。产业链中游种植体生产商 主要有通策医疗、正海生物、康拓医疗等企业;器械经销商主要有国药控股、上海医药等旗下器械分销 平台。产业链下游医疗机构主要包络瑞尔集团、牙博士口腔、美奥口腔等。 行业主要上市公司：通策医疗(600763)、奥精医疗(688613)、瑞尔集团(6639.HK)、牙博士(874689)、可 恩口腔(830938)、蓝天口腔(873101)、华齿口腔(873311)、华美牙科(833269)等 本文核心数据：口腔种植行业全产业链;区域热力图;代表性企业产业链布局 1、中国口腔种植产业链全景梳理 从产业链结构来看，口腔种植产业链上游主要包括原材料与核心部件供应商、设备制造商以及软件开发 商。其中原材料主要包括金属材料，如提供钛及钛合金的厂商，这是种植体的主要材料，因其具有良好 的生物相容性和机械性能;还有陶瓷材料供应商，如生产氧化锆、生物玻璃陶瓷等的厂商，这些材料常 用于制作牙冠等修复体;此外，提供其他生物降解材料 ...

1、OssaNova™人工骨修复材料 注册证编号：2502543ĐKLH/BYT-HTTB 产品名称：人工骨修复材料 证件有效期：2025.07.16-永久有效 证券代码：688613 证券简称：奥精医疗 公告编号：2025-038 奥精医疗科技股份有限公司 自愿披露关于公司产品在越南获得注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2024年12月向越南卫生部 递交了公司人工骨修复材料的注册申报资料。公司于近日收到越南卫生部通知，公 司人工骨修复材料获得批准。现将相关情况公告如下： 一、注册证内容 奥精医疗科技股份有限公司董事会 2025年7 月 22 日 产品分类：D类（高风险医疗器械） 二、医疗器械基本情况 1、OssaNova™人工骨修复材料 本次获得越南注册证的OssaNova™人工骨修复材料是基于奥精医疗具有完全自主 知识产权的体外仿生矿化技术研发和生产的一种仿生矿化胶原人工骨修复材料，在 组成成分和微观结构上均对人体天然骨组织高度仿生。产品用于口腔 ...

截至2025年7月11日收盘，奥精医疗（688613）报收于18.31元，较上周的18.27元上涨0.22%。本周，奥 精医疗7月7日盘中最高价报18.77元。7月10日盘中最低价报17.7元。奥精医疗当前最新总市值25.09亿 元，在医疗器械板块市值排名113/126，在两市A股市值排名4692/5149。 奥精医疗2025年第一次临时股东大会于2025年7月11日在北京召开，出席股东和代理人人数89人，持有 表决权数量26,135,097股，占公司表决权数量的19.0755%。会议审议通过了关于部分募投项目调整实施 主体、实施地点及部分募投项目子项目调整的议案，表决结果为：同意25,800,341股，占98.7191%，反 对318,485股，占1.2186%，弃权16,271股，占0.0623%。北京市中伦律师事务所律师见证了本次股东大 会，认为会议的召集和召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜均 符合相关法律法规及《公司章程》的有关规定，表决结果合法、有效。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 ...

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 first extraordinary general meeting of shareholders of Aojing Medical Technology Co., Ltd. comply with relevant laws and regulations [1][5][6]. Group 1: Meeting Procedures - The company published the notice for the extraordinary general meeting on June 26, 2025, which included details such as meeting time, voting methods, and agenda items, with a notice period of 15 days before the meeting [2][3]. - The meeting was held on July 11, 2025, at a specified location, and was presided over by the company's chairman, Eric Gang Hu [3]. Group 2: Attendance and Qualifications - A total of 89 shareholders and authorized agents attended the meeting, holding 26,135,097 shares, which represents a significant portion of the voting rights as of the registration date [5][6]. - The qualifications of the attendees and the convenor of the meeting were verified to be in accordance with the relevant laws and the company's articles of association [5][6]. Group 3: Voting Procedures and Results - The voting process combined both on-site and online methods, with results being counted and announced immediately after the meeting [7]. - The meeting approved the agenda items as listed in the notice, and there were no objections raised regarding the voting results [7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including convening, attendance, and voting procedures, were conducted in compliance with applicable laws and regulations, rendering the results valid [5][7].

1 法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》 《股东会规则》等相关法律、法规、规章、规范性文件及《公司章程》的规定发 表意见，并不对会议审议的议案内容以及该等议案所表述的事实或数据的真实性 及准确性发表意见。本所仅根据现行有效的中国法律问题发表意见，而未对有关 会计、审计和资产评估等非法律专业事项发表意见，亦未对非中国法律问题发表 意见。 本所同意将本法律意见书作为本次股东大会的公告材料，随同其他会议文件 一并报送有关机构并公告。本法律意见书仅供公司为本次股东大会之目的而使用， 未经本所书面同意，本法律意见书不得用于任何其他目的。 北京市中伦律师事务所 关于奥精医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2025 年第一次临时股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-037 奥精医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 11 日 （二） 股东大会召开的地点：北京市大兴区庆丰西路 69 号 35 号楼 3 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 89 | | --- | --- | | 普通股股东人数 | 89 | | 2、出席会议的股东所持有的表决权数量 | 26,135,097 | | 普通股股东所持有表决权数量 | 26,135,097 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 19.0755 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 19.0755 | （五） ...

Company Summary - Aojing Medical (688613) reported a significant increase in sales volume of its core product "Gaojin," with a year-on-year growth of 93.54% in 2024, selling 1.4714 million cm3 compared to 760,300 cm3 in 2023 [1] - In Q1 2025, the sales volume of "Gaojin" further accelerated, achieving a remarkable growth of 174% [1] - The price of artificial bone products, including "Gaojin," decreased significantly due to centralized procurement, with prices dropping from 1,000-1,500 RMB/cm3 to 320-340 RMB/cm3, allowing more patients to access these materials [1] Industry Overview - The domestic bone repair market is in a phase of continuous expansion, with significant growth potential for artificial bone, particularly biomimetic mineralized collagen materials [3] - The market size of bone repair materials in China was approximately 2.58 billion RMB in 2023, with a projected compound annual growth rate (CAGR) of 14.5% from 2022 to 2028 [3] - Artificial bone materials are becoming the primary clinical application consumables in the bone repair field, overcoming the limitations of autologous and natural bone [3]

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Aojing Medical Technology Co., Ltd. in 2024, including a significant decline in revenue and net profit due to price reductions from centralized procurement and increased competition in the medical device market [2][11]. Summary by Sections Business Performance - In 2024, the company's main business revenue was impacted by a decrease in the ex-factory price of artificial bones due to centralized procurement, leading to a net profit of -12.66 million yuan, a year-on-year decrease of 123.35% [2][11]. - The revenue from the neurosurgery product "Cerebrum" was 13.85 million yuan, down 70.07% year-on-year [2][11]. - The company reported a significant increase in sales volume of its orthopedic product "Guanjin," with a total sales volume of 1.4714 million cm³ in 2024, a 93.54% increase from 2023 [5][11]. Product Analysis - The centralized procurement led to a drop in the clinical terminal price of artificial bones from 1,000-1,500 yuan/cm³ to 320-340 yuan/cm³, which increased the accessibility of artificial bones for patients [5][11]. - The oral product "Zhibei" saw a substantial revenue increase due to new high-quality distributor partnerships, contributing 30.84 million yuan, accounting for 78.44% of its total revenue [5][16]. Regional Sales Concentration - The company's sales are primarily concentrated in East and North China, where it has established a strong presence with over 200 hospitals using its products [7][11]. - The concentration in these regions is attributed to the availability of advanced medical resources and the acceptance of innovative medical products [7][11]. Sales Expenses - Sales expenses increased significantly due to the expansion of the sales team and marketing efforts related to the centralized procurement and the acquisition of HumanTech Dental [9][11]. - The increase in travel expenses was driven by a higher number of terminal hospitals and the need for market support activities [9][11]. Financial Challenges - The company's performance turned from profit to loss due to several factors, including reduced profit margins from centralized procurement, declining neurosurgery product revenue, and increased operating costs [11][10]. - The overall gross margin for the orthopedic product "Guanjin" fell to 72.84%, a decrease of 11.03 percentage points year-on-year [10][11]. Acquisition of HumanTech Dental - The acquisition of HumanTech Dental was completed in 2024, with a goodwill of 24.62 million yuan, although the acquired company has not yet achieved profitability [20][21]. - The integration of HumanTech Dental's operations is aimed at expanding the company's market presence in the dental implant sector [21][22]. Accounts Receivable - The accounts receivable increased by 13.31% year-on-year, with the company extending credit terms to some high-quality distributors to support their sales efforts [17][19]. - The company has a bad debt provision ratio of 13.55%, indicating a cautious approach to credit risk management [17][19].

01 c 立信会计师事务所（特殊普通合伙） 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管 间询函的回复 信会师函字[2025]第 ZB113 号 立信会计师事务所(特殊普通合伙) 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管问询函的回复 信会师函字[2025]第 ZB113 号 上海证券交易所科创板公司管理部: 根据贵所出具的《关于奥精医疗科技股份有限公司 2024 年年度报告的信息 披露监管问询函》(以下简称"问询函")的有关要求,立信会计师事务所(特 殊普通合伙）(以下简称"年审会计师"或"我们")作为奥精医疗科技股份有 限公司（以下简称"奥精医疗"或"公司"）的 2024 年年度审计报告会计师事 务所,对问询函中提到的需要年审会计师发表意见的问题进行了认真核查,具体 回复内容如下: 说明:本回复报告中若出现总计数尾数与所列数值总和尾数不符的情况, 均为四舍五入所致。 问题 -- 关于主营业务与经营业绩。年报披露，（1）2024 年公司主营业务收入 20,043.09 万元,同比下滑 8.24%,其中骨科、神经外科业务收入分别同比下滑 3.83%、70.07%，口腔 ...